These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33987441)

  • 1. Characterization and Pharmacokinetic Evaluation of Oxaliplatin Long-Circulating Liposomes.
    Cheraga N; Ouahab A; Shen Y; Huang NP
    Biomed Res Int; 2021; 2021():5949804. PubMed ID: 33987441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin.
    Li Y; Xu P; He D; Xu B; Tu J; Shen Y
    Int J Nanomedicine; 2020; 15():6721-6734. PubMed ID: 32982229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
    Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
    Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
    Ando H
    Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
    Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
    Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma.
    Yang C; Liu HZ; Fu ZX; Lu WD
    BMC Biotechnol; 2011 Mar; 11():21. PubMed ID: 21401960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats.
    Ito Y; Kobuchi S; Shimizu R; Katsuyama Y
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):155-161. PubMed ID: 29164296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats.
    Kobuchi S; Katsuyama Y; Ito Y
    Xenobiotica; 2020 Feb; 50(2):223-230. PubMed ID: 30938550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
    Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.
    Matsuo NCA; Ando H; Doi Y; Shimizu T; Ishima Y; Ishida T
    Chem Pharm Bull (Tokyo); 2022; 70(5):351-358. PubMed ID: 35491191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells].
    Zhang Y; Sun XW; Xu JH; Lu H; Fan ZZ; Sun J; Zhang XX
    Zhong Xi Yi Jie He Xue Bao; 2012 Aug; 10(8):901-10. PubMed ID: 22883407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer.
    Ito Y; Kobuchi S; Takesada W; Takahashi C
    Anticancer Res; 2019 Aug; 39(8):4207-4213. PubMed ID: 31366507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
    Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
    Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
    Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
    J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
    Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
    Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the use of sPLA
    Pourhassan H; Clergeaud G; Hansen AE; Østrem RG; Fliedner FP; Melander F; Nielsen OL; O'Sullivan CK; Kjær A; Andresen TL
    J Control Release; 2017 Sep; 261():163-173. PubMed ID: 28662900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.